Trial Profile
An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CheckMate 907
- Sponsors Bristol-Myers Squibb
- 25 May 2022 Status changed from active, no longer recruiting to completed.
- 11 Mar 2022 Planned primary completion date changed from 7 Mar 2021 to 16 Feb 2021.
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer